PLX
Protalix Biotherapeutics Inc
2.80$
-1.4%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 47.3% | 84.5% | 69.4% | 70.2% | 46.6% | 21.3% | 80.9% | 37.5% | 46.6% | 50.6% | 12.2% | 39.0% | 30.8% | |
| 52.7% | 15.5% | 30.6% | 29.8% | 53.4% | 78.7% | 19.1% | 62.5% | 53.4% | 49.4% | 87.8% | 61.0% | 69.2% | |
| 35.5% | 29.6% | 77.0% | 22.0% | 16.7% | 22.6% | 34.4% | 38.3% | 25.0% | 61.8% | 16.1% | 21.9% | 24.7% | |
| 62.8% | 185.9% | 15.0% | 72.9% | 84.9% | 86.8% | 25.7% | 16.8% | 16.4% | 38.7% | 12.9% | 15.6% | 17.3% | |
| 70.9% | 69.1% | 160.1% | 47.8% | 31.1% | 39.1% | 60.1% | 55.0% | 41.4% | 100.4% | 25.1% | 37.5% | 40.3% | |
| -18.2% | -53.5% | -129.6% | -18.0% | 22.2% | 39.6% | -41.0% | 7.5% | 11.9% | -51.1% | 62.7% | 23.5% | 28.9% | |
| 4.4% | 7.4% | 10.4% | 2.7% | 1.7% | 0.0% | 0.1% | 5.0% | 1.0% | 4.2% | 0.6% | 2.5% | 1.6% | |
| -16.6% | -61.3% | -126.3% | -16.9% | 21.4% | 40.2% | -36.9% | 4.2% | 12.5% | -52.4% | 62.6% | 24.4% | 29.1% | |
| 1.3% | -3.6% | -3.7% | -0.5% | 3.4% | 4.5% | -1.1% | 3.2% | -0.6% | 8.0% | 8.4% | 5.4% | 5.6% | |
| -17.9% | -57.6% | -122.6% | -16.4% | 18.0% | 35.6% | -35.8% | 1.0% | 13.2% | -60.3% | 54.3% | 19.0% | 23.5% | |
| -9.2% | -50.9% | -107.3% | -11.8% | 24.9% | 42.0% | -33.4% | 11.5% | 15.6% | -43.9% | 64.4% | 29.0% | 32.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.